Long-Term Outcome of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Renal Involvement
Background: Despite treatment, renal involvement in antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis is still associated with significant long-term mortality and remains an important cause of end-stage renal failure. Methods: We retrospectively analyzed a series of 61 consecutive p...
Gespeichert in:
Veröffentlicht in: | Kidney & blood pressure research 2005-01, Vol.28 (3), p.144-152 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 152 |
---|---|
container_issue | 3 |
container_start_page | 144 |
container_title | Kidney & blood pressure research |
container_volume | 28 |
creator | Rihova, Zuzana Jancova, Eva Merta, Miroslav Rysava, Romana Reiterova, Jana Zabka, Jiri Tesař, Vladimir |
description | Background: Despite treatment, renal involvement in antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis is still associated with significant long-term mortality and remains an important cause of end-stage renal failure. Methods: We retrospectively analyzed a series of 61 consecutive patients with newly diagnosed ANCA-associated renal vasculitis (54.1% Wegener’s granulomatosis, 23% renal-limited vasculitis, 16.4% microscopic polyangiitis, 4.9% Churg-Strauss syndrome) diagnosed between 1986 and 1997. Results: The median creatinine level at diagnosis was 221.5 (63–762) µmol/l, i.e. 2.5 (0.7–8.6) mg/dl, 32.8% were dialysis-dependent. All patients were treated with cyclophosphamide. Remission was achieved in 87% of patients. Relapses occurred in 44.7%. The median renal disease-free interval was 62.5 (0–138) months. The estimated patient survival at 5 and 10 years was 78.3 and 62.2%, respectively. Mortality was associated with age (p = 0.04 when age limit 50 years) and advanced renal failure (p = 0.038 when compared dialysis-dependent and independent patients). Estimated renal survival time at 5 and 10 years was 69.2 and 55.8%, respectively. At the end of follow-up, 50.8% of patients were in complete remission, 31% had died. The median serum creatinine level was 137.5 (77–469) µmol/l, i.e. 1.56 (0.87–5.3) mg/dl, 24.6% of patients were on regular dialysis treatment. Conclusion: Patient survival, relapse rate and mortality were comparable to similar reports. In view of the severity of the renal disease and the length of follow-up, renal survival was very good. Despite effective treatment, the long-term outcome of patients with ANCA-associated renal vasculitis remains unsatisfactory. |
doi_str_mv | 10.1159/000085854 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_15908752</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20925472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-b33d2ad27a68de50d4d57fb20feee0aa287e54704e3e5f5b2640c1f2651048523</originalsourceid><addsrcrecordid>eNpd0c9LwzAUB_AgipvTg2dBggfBQzVJk7Y7luGPwWAi02tJ29cts21mkm7svzdzQ8FcXuB93peQh9AlJfeUiuED8ScRieBHqE85CwNCeXj8cycBJ8Ooh86sXXolCGGnqOeHSBIL1kebiW7nwQxMg6edK3QDWFf4VToFrbN4o9wCp61TLXTO6NVC1Xi0dXpVS9uoAqed09K3c11ug9RaXSjpoMQf0hZdrZw6RLxBK2s8bte6XkPjo8_RSSVrCxeHOkDvT4-z0UswmT6PR-kkKMKIuiAPw5LJksUySkoQpOSliKuckQoAiJQsiUHwmHAIQVQiZxEnBa1YJCjhiWDhAN3uc1dGf3VgXdYoW0BdyxZ0ZzNGhswH7ODNP7jUnfGv9oZxStkwoh7d7VFhtLUGqmxlVCPNNqMk260i-12Ft9eHwC5voPyTh7_34GoPPqWZg_kF-_Fv5tGNoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>224112961</pqid></control><display><type>article</type><title>Long-Term Outcome of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Renal Involvement</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Rihova, Zuzana ; Jancova, Eva ; Merta, Miroslav ; Rysava, Romana ; Reiterova, Jana ; Zabka, Jiri ; Tesař, Vladimir</creator><creatorcontrib>Rihova, Zuzana ; Jancova, Eva ; Merta, Miroslav ; Rysava, Romana ; Reiterova, Jana ; Zabka, Jiri ; Tesař, Vladimir</creatorcontrib><description>Background: Despite treatment, renal involvement in antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis is still associated with significant long-term mortality and remains an important cause of end-stage renal failure. Methods: We retrospectively analyzed a series of 61 consecutive patients with newly diagnosed ANCA-associated renal vasculitis (54.1% Wegener’s granulomatosis, 23% renal-limited vasculitis, 16.4% microscopic polyangiitis, 4.9% Churg-Strauss syndrome) diagnosed between 1986 and 1997. Results: The median creatinine level at diagnosis was 221.5 (63–762) µmol/l, i.e. 2.5 (0.7–8.6) mg/dl, 32.8% were dialysis-dependent. All patients were treated with cyclophosphamide. Remission was achieved in 87% of patients. Relapses occurred in 44.7%. The median renal disease-free interval was 62.5 (0–138) months. The estimated patient survival at 5 and 10 years was 78.3 and 62.2%, respectively. Mortality was associated with age (p = 0.04 when age limit 50 years) and advanced renal failure (p = 0.038 when compared dialysis-dependent and independent patients). Estimated renal survival time at 5 and 10 years was 69.2 and 55.8%, respectively. At the end of follow-up, 50.8% of patients were in complete remission, 31% had died. The median serum creatinine level was 137.5 (77–469) µmol/l, i.e. 1.56 (0.87–5.3) mg/dl, 24.6% of patients were on regular dialysis treatment. Conclusion: Patient survival, relapse rate and mortality were comparable to similar reports. In view of the severity of the renal disease and the length of follow-up, renal survival was very good. Despite effective treatment, the long-term outcome of patients with ANCA-associated renal vasculitis remains unsatisfactory.</description><identifier>ISSN: 1420-4096</identifier><identifier>EISSN: 1423-0143</identifier><identifier>DOI: 10.1159/000085854</identifier><identifier>PMID: 15908752</identifier><identifier>CODEN: RPBIEL</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Antineutrophil Cytoplasmic ; Cyclophosphamide - therapeutic use ; Disease-Free Survival ; Drug Evaluation ; Humans ; Kidney Diseases - drug therapy ; Kidney Diseases - etiology ; Kidney Diseases - mortality ; Kidney Failure, Chronic - etiology ; Middle Aged ; Original Paper ; Recurrence ; Remission Induction ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Vasculitis - drug therapy ; Vasculitis - immunology ; Vasculitis - mortality</subject><ispartof>Kidney & blood pressure research, 2005-01, Vol.28 (3), p.144-152</ispartof><rights>2005 S. Karger AG, Basel</rights><rights>Copyright (c) 2005 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-b33d2ad27a68de50d4d57fb20feee0aa287e54704e3e5f5b2640c1f2651048523</citedby><cites>FETCH-LOGICAL-c361t-b33d2ad27a68de50d4d57fb20feee0aa287e54704e3e5f5b2640c1f2651048523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15908752$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rihova, Zuzana</creatorcontrib><creatorcontrib>Jancova, Eva</creatorcontrib><creatorcontrib>Merta, Miroslav</creatorcontrib><creatorcontrib>Rysava, Romana</creatorcontrib><creatorcontrib>Reiterova, Jana</creatorcontrib><creatorcontrib>Zabka, Jiri</creatorcontrib><creatorcontrib>Tesař, Vladimir</creatorcontrib><title>Long-Term Outcome of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Renal Involvement</title><title>Kidney & blood pressure research</title><addtitle>Kidney Blood Press Res</addtitle><description>Background: Despite treatment, renal involvement in antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis is still associated with significant long-term mortality and remains an important cause of end-stage renal failure. Methods: We retrospectively analyzed a series of 61 consecutive patients with newly diagnosed ANCA-associated renal vasculitis (54.1% Wegener’s granulomatosis, 23% renal-limited vasculitis, 16.4% microscopic polyangiitis, 4.9% Churg-Strauss syndrome) diagnosed between 1986 and 1997. Results: The median creatinine level at diagnosis was 221.5 (63–762) µmol/l, i.e. 2.5 (0.7–8.6) mg/dl, 32.8% were dialysis-dependent. All patients were treated with cyclophosphamide. Remission was achieved in 87% of patients. Relapses occurred in 44.7%. The median renal disease-free interval was 62.5 (0–138) months. The estimated patient survival at 5 and 10 years was 78.3 and 62.2%, respectively. Mortality was associated with age (p = 0.04 when age limit 50 years) and advanced renal failure (p = 0.038 when compared dialysis-dependent and independent patients). Estimated renal survival time at 5 and 10 years was 69.2 and 55.8%, respectively. At the end of follow-up, 50.8% of patients were in complete remission, 31% had died. The median serum creatinine level was 137.5 (77–469) µmol/l, i.e. 1.56 (0.87–5.3) mg/dl, 24.6% of patients were on regular dialysis treatment. Conclusion: Patient survival, relapse rate and mortality were comparable to similar reports. In view of the severity of the renal disease and the length of follow-up, renal survival was very good. Despite effective treatment, the long-term outcome of patients with ANCA-associated renal vasculitis remains unsatisfactory.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Antineutrophil Cytoplasmic</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Drug Evaluation</subject><subject>Humans</subject><subject>Kidney Diseases - drug therapy</subject><subject>Kidney Diseases - etiology</subject><subject>Kidney Diseases - mortality</subject><subject>Kidney Failure, Chronic - etiology</subject><subject>Middle Aged</subject><subject>Original Paper</subject><subject>Recurrence</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Vasculitis - drug therapy</subject><subject>Vasculitis - immunology</subject><subject>Vasculitis - mortality</subject><issn>1420-4096</issn><issn>1423-0143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0c9LwzAUB_AgipvTg2dBggfBQzVJk7Y7luGPwWAi02tJ29cts21mkm7svzdzQ8FcXuB93peQh9AlJfeUiuED8ScRieBHqE85CwNCeXj8cycBJ8Ooh86sXXolCGGnqOeHSBIL1kebiW7nwQxMg6edK3QDWFf4VToFrbN4o9wCp61TLXTO6NVC1Xi0dXpVS9uoAqed09K3c11ug9RaXSjpoMQf0hZdrZw6RLxBK2s8bte6XkPjo8_RSSVrCxeHOkDvT4-z0UswmT6PR-kkKMKIuiAPw5LJksUySkoQpOSliKuckQoAiJQsiUHwmHAIQVQiZxEnBa1YJCjhiWDhAN3uc1dGf3VgXdYoW0BdyxZ0ZzNGhswH7ODNP7jUnfGv9oZxStkwoh7d7VFhtLUGqmxlVCPNNqMk260i-12Ft9eHwC5voPyTh7_34GoPPqWZg_kF-_Fv5tGNoA</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>Rihova, Zuzana</creator><creator>Jancova, Eva</creator><creator>Merta, Miroslav</creator><creator>Rysava, Romana</creator><creator>Reiterova, Jana</creator><creator>Zabka, Jiri</creator><creator>Tesař, Vladimir</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7T5</scope></search><sort><creationdate>20050101</creationdate><title>Long-Term Outcome of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Renal Involvement</title><author>Rihova, Zuzana ; Jancova, Eva ; Merta, Miroslav ; Rysava, Romana ; Reiterova, Jana ; Zabka, Jiri ; Tesař, Vladimir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-b33d2ad27a68de50d4d57fb20feee0aa287e54704e3e5f5b2640c1f2651048523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Antineutrophil Cytoplasmic</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Drug Evaluation</topic><topic>Humans</topic><topic>Kidney Diseases - drug therapy</topic><topic>Kidney Diseases - etiology</topic><topic>Kidney Diseases - mortality</topic><topic>Kidney Failure, Chronic - etiology</topic><topic>Middle Aged</topic><topic>Original Paper</topic><topic>Recurrence</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Vasculitis - drug therapy</topic><topic>Vasculitis - immunology</topic><topic>Vasculitis - mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rihova, Zuzana</creatorcontrib><creatorcontrib>Jancova, Eva</creatorcontrib><creatorcontrib>Merta, Miroslav</creatorcontrib><creatorcontrib>Rysava, Romana</creatorcontrib><creatorcontrib>Reiterova, Jana</creatorcontrib><creatorcontrib>Zabka, Jiri</creatorcontrib><creatorcontrib>Tesař, Vladimir</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>Immunology Abstracts</collection><jtitle>Kidney & blood pressure research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rihova, Zuzana</au><au>Jancova, Eva</au><au>Merta, Miroslav</au><au>Rysava, Romana</au><au>Reiterova, Jana</au><au>Zabka, Jiri</au><au>Tesař, Vladimir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Outcome of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Renal Involvement</atitle><jtitle>Kidney & blood pressure research</jtitle><addtitle>Kidney Blood Press Res</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>28</volume><issue>3</issue><spage>144</spage><epage>152</epage><pages>144-152</pages><issn>1420-4096</issn><eissn>1423-0143</eissn><coden>RPBIEL</coden><abstract>Background: Despite treatment, renal involvement in antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis is still associated with significant long-term mortality and remains an important cause of end-stage renal failure. Methods: We retrospectively analyzed a series of 61 consecutive patients with newly diagnosed ANCA-associated renal vasculitis (54.1% Wegener’s granulomatosis, 23% renal-limited vasculitis, 16.4% microscopic polyangiitis, 4.9% Churg-Strauss syndrome) diagnosed between 1986 and 1997. Results: The median creatinine level at diagnosis was 221.5 (63–762) µmol/l, i.e. 2.5 (0.7–8.6) mg/dl, 32.8% were dialysis-dependent. All patients were treated with cyclophosphamide. Remission was achieved in 87% of patients. Relapses occurred in 44.7%. The median renal disease-free interval was 62.5 (0–138) months. The estimated patient survival at 5 and 10 years was 78.3 and 62.2%, respectively. Mortality was associated with age (p = 0.04 when age limit 50 years) and advanced renal failure (p = 0.038 when compared dialysis-dependent and independent patients). Estimated renal survival time at 5 and 10 years was 69.2 and 55.8%, respectively. At the end of follow-up, 50.8% of patients were in complete remission, 31% had died. The median serum creatinine level was 137.5 (77–469) µmol/l, i.e. 1.56 (0.87–5.3) mg/dl, 24.6% of patients were on regular dialysis treatment. Conclusion: Patient survival, relapse rate and mortality were comparable to similar reports. In view of the severity of the renal disease and the length of follow-up, renal survival was very good. Despite effective treatment, the long-term outcome of patients with ANCA-associated renal vasculitis remains unsatisfactory.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>15908752</pmid><doi>10.1159/000085854</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1420-4096 |
ispartof | Kidney & blood pressure research, 2005-01, Vol.28 (3), p.144-152 |
issn | 1420-4096 1423-0143 |
language | eng |
recordid | cdi_pubmed_primary_15908752 |
source | MEDLINE; Karger Journals Complete |
subjects | Adolescent Adult Aged Aged, 80 and over Antibodies, Antineutrophil Cytoplasmic Cyclophosphamide - therapeutic use Disease-Free Survival Drug Evaluation Humans Kidney Diseases - drug therapy Kidney Diseases - etiology Kidney Diseases - mortality Kidney Failure, Chronic - etiology Middle Aged Original Paper Recurrence Remission Induction Retrospective Studies Survival Rate Treatment Outcome Vasculitis - drug therapy Vasculitis - immunology Vasculitis - mortality |
title | Long-Term Outcome of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Renal Involvement |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T13%3A14%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Outcome%20of%20Patients%20with%20Antineutrophil%20Cytoplasmic%20Autoantibody-Associated%20Vasculitis%20with%20Renal%20Involvement&rft.jtitle=Kidney%20&%20blood%20pressure%20research&rft.au=Rihova,%20Zuzana&rft.date=2005-01-01&rft.volume=28&rft.issue=3&rft.spage=144&rft.epage=152&rft.pages=144-152&rft.issn=1420-4096&rft.eissn=1423-0143&rft.coden=RPBIEL&rft_id=info:doi/10.1159/000085854&rft_dat=%3Cproquest_pubme%3E20925472%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=224112961&rft_id=info:pmid/15908752&rfr_iscdi=true |